As I reported earlier this month, colon cancer rates are on the rise—especially among young people. And the terrible misuse of antibiotic drugs may be to blame!
But no matter your age, you don’t have to be colon cancer’s next victim.
Because research shows you can CRUSH your risk of ever developing colon cancer by taking a safe, science-backed, inexpensive, over-the-counter (OTC) remedy that derives from folk medicine.
And the best part? It’s never too late to start up this new preventative regimen!
Here’s what I’m talking about…
Safe OTC drug slashes colon cancer risk
As you know, aspirin is a naturally derived, OTC medication that’s been used—SAFELY—by millions of Americans for more than a century.
In fact, it first entered the U.S. market as a drug in 1898—eight years before the forerunner of the U.S. Food and Drug Administration (FDA) even existed. Then, the FDA “grandfathered” it in as an “existing” drug in 1938 because of its long history as a safe, effective medication.
Of course, most people take aspirin as a pain reliever. But many also take daily, low doses (usually 81 mg) of it to help prevent heart attacks and strokes. (Its anticoagulant effects reduce the risk of blood clots, which are typically a final, potentially fatal, step in the chain of events that lead to heart attacks and strokes.)
And now, for this new study, researchers looked at the effect of low-dose aspirin on colon cancer risk…
They surveyed more than 5,000 healthy, middle-aged men and women about their regular, low-dose aspirin use over a roughly 20-year period. They then defined “regular” aspirin use as taking 15 or more pills per month.
Next, they sorted the participants as “short-term” or “long-term” regular aspirin users, based on the answers given in the survey.
It turns out, long-term, regular users of aspirin PRIOR to colon cancer diagnosis had an impressive 31 percent lower risk of dying from the disease.
In addition, they had a 27 percent lower risk of getting distant metastatic growths. (This point is key—because it means aspirin lowers the risk of the cancer becoming deadly and spreading to other parts of the body. And—of course—once a cancer has metastasized, the mainstream has no way to “cure” it.)
Best of all, it seems that it’s never too late to start on an aspirin regimen, either…
In fact, participants who began regular aspirin use AFTER their colon cancer diagnosis still had a 40 percent lower risk of dying compared to those who did not ever use aspirin.
The researchers said they think low-dose aspirin protects against colon cancer because it PERMANENTLY prevents blood cells called platelets from activating and producing an enzyme that allows them to clump together. And when colon cancer tumor cells can’t attach to these clumps, they simply can’t grow and spread throughout the body.
Now, I should note that aspirin can increase gastrointestinal (GI) irritation and bleeding risk—primarily in people with a family history. But, overall, that risk appears to be very low, if you take it as directed. (Of course, if you’re concerned about these potential effects, talk with your healthcare provider. And consider taking a buffered aspirin to eliminate GI effects—which includes an antacid.)
Use common sense and be your own advocate
If you have a high risk of developing colon cancer, I encourage you to speak with your doctor about this new study and the possibility of adding a daily, low-dose aspirin to your regimen. (If you’re not already doing so!)
I also suggest you follow these five, simple steps that can cut your colon cancer risk in HALF.
Of course, in addition to following these sensible guidelines, you have dozens of other safe, natural alternatives to help prevent, detect, AND treat colon cancer. I’ve outlined them all in detail in my groundbreaking online learning tool, my Authentic Anti-Cancer Protocol. To learn more, or to enroll today, click here now!
“Associations of Aspirin and Non-Aspirin Non-Steroidal Anti-Inflammatory Drugs With Colorectal Cancer Mortality After Diagnosis.” JNCI: Journal of the National Cancer Institute, July 2021; 113(7): 833–840, doi.org/10.1093/jnci/djab008